201 filings
Page 4 of 11
8-K
55uw 48s1zcbcqx6m
12 May 22
Regulation FD Disclosure
8:01am
8-K
jscc 8kp4zqaaqk
5 May 22
Evofem Biosciences Announces 1-for-15 Reverse Stock Split
9:03am
8-K
7al7jxp 4dl
4 May 22
Evofem Biosciences Reports First Quarter 2022
4:05pm
8-K
bisfk7
7 Apr 22
Continued Listing Subject to Receipt of Shareholder Approval for the Reverse Stock Split of
6:51am
8-K
legc z92oq7w0drc1j
6 Apr 22
Entry into a Material Definitive Agreement
7:36pm
8-K
qva0x
24 Mar 22
Entry into a Material Definitive Agreement
4:03pm
8-K
and0by4j9hsx9o
21 Mar 22
Entry into a Material Definitive Agreement
4:35pm
8-K
evo7l2agrd77sqh
3 Mar 22
Evofem Biosciences Reports Fourth Quarter and Year-End 2021
4:11pm
8-K
crqo j09t
1 Mar 22
Entry into a Material Definitive Agreement
10:53am
8-K
fxn h1q1j3nfg2qrbz
28 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K/A
f1sjf4y 36k
16 Feb 22
Entry into a Material Definitive Agreement
4:05pm
8-K
5ha380299o
16 Feb 22
Entry into a Material Definitive Agreement
6:22am
8-K
q4b14w
15 Feb 22
Regulation FD Disclosure
4:10pm
8-K
zzmwy1lvsp223k iuldb
19 Jan 22
Evofem Biosciences Announces Record Net Sales and Phexxi Prescriptions in Q4 2021
9:01am
8-K
y1bfn3won85ai
13 Jan 22
Entry into a Material Definitive Agreement
8:43am
8-K
nxcwhux5
15 Dec 21
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
3fju1yck568brw65tf
9 Dec 21
Evofem Biosciences Expects Record High Phexxi Prescriptions and Strong Net Revenue Growth in Fourth Quarter 2021
8:00am
8-K
89tth053 0an
8 Dec 21
Other Events
6:30am
8-K
kwb44hjnnqlvmhc4vt
22 Nov 21
Entry into a Material Definitive Agreement
6:50am
8-K
ix6omc1za3
19 Nov 21
Departure of Directors or Certain Officers
4:10pm